Oliver Hartley, Orion’s Vice-President Drug Discovery, will present Orion’s novel technology for targeting Hartley will also present new data on Orion’s CCR2 antagonist, OB-004, demonstrating the ability of this

Oliver Hartley. Below is your Classified GPCR News at a glance for March 20th to 26th, 2023.

Oliver Hartley, Dr. Pierre Eftekhari, Dr. Lauren Slosky, Dr. Christel Menet, Dr. Ben Myers and Dr.

Inês Pinheiro and Oliver Hartley from the Orion Biotechnology team on their recent study on Arylsulfatases

Oliver Hartley, was at the PEGS Europe Novartis pays Legend $100M upfront to give solid tumor CAR-T the

Relevant Publications Development of Orion’s platform technology Hartley, O. et al. (2004) Proceedings